How to use the speech recognition tool?

RET-IRD-04

RET-IRD-04

Efficacy and safety of QLT091001 in subjects with Inherited Retinal Disease (IRD) caused by gene mutations.

Type: Interventional



Status of the trial: Unknown

Orphan Drug Recognition: No

Inclusion

  • Opening Date: 2017-12-12
  • Closing Date: 2018-12-12

Criteria

Inclusion: Genotype-confirmed Leber congenital amaurosis attributable

Exclusion: Prior gene therapy

Children: No

Adults: No

Funder Type: industry

HCP: Principal investigators

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: